Abstract
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
| Original language | English |
|---|---|
| Number of pages | 7 |
| Journal | British Journal of Clinical Pharmacology |
| DOIs | |
| Publication status | E-pub ahead of print - 9 Aug 2019 |
Cite this
}
Optimising low-dose methotrexate for rheumatoid arthritis-A review. / Lucas, Catherine J.; Dimmitt, Simon B.; Martin, Jennifer H.
In: British Journal of Clinical Pharmacology, 09.08.2019.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Optimising low-dose methotrexate for rheumatoid arthritis-A review
AU - Lucas, Catherine J.
AU - Dimmitt, Simon B.
AU - Martin, Jennifer H.
PY - 2019/8/9
Y1 - 2019/8/9
N2 - Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
AB - Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
KW - clinical pharmacology
KW - methotrexate
KW - pharmacodynamics
KW - pharmacokinetics
KW - prescribing
KW - rheumatoid arthritis
KW - MODIFYING ANTIRHEUMATIC DRUGS
KW - PULSE METHOTREXATE
KW - SUBCUTANEOUS METHOTREXATE
KW - ORAL METHOTREXATE
KW - DISEASE-ACTIVITY
KW - DOUBLE-BLIND
KW - RISK-FACTORS
KW - POLYGLUTAMATE CONCENTRATIONS
KW - COMBINATION THERAPY
KW - AMERICAN-COLLEGE
U2 - 10.1111/bcp.14057
DO - 10.1111/bcp.14057
M3 - Review article
JO - British Journal Clinical Pharmacology
JF - British Journal Clinical Pharmacology
SN - 0306-5251
ER -